A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)
Launched by PFIZER · Mar 31, 2008
Trial Information
Current as of July 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with symptomatic OA of the knee by the American College of Rheumatology (ACR) criteria and a Functional Capacity Classification (FCC) of I - III at Screening Visit and were walking
- • At the Baseline visit, eligible patients were to have Patient's Assessment of Arthritis Pain VAS ≥ 40 mm and Patient's \& Physician's Global Assessment of Arthritis of "Poor" or "Very Poor"
- Exclusion Criteria:
- • Patients unable to walk generally
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sapporo, Hokkaido, Japan
Yokohama, Kanagawa, Japan
Setagaya Ku, Tokyo, Japan
Itabashi Ku, Tokyo, Japan
Shinjuku Ku, Tokyo, Japan
Tokyo, , Japan
Sakura, Chiba, Japan
Kurume, Fukuoka, Japan
Iizuka, Fukuoka, Japan
Kamakura, Kanagawa, Japan
Chitose, Hokkaido, Japan
Saga, , Japan
Funabashi, Chiba, Japan
Chikushi Gun, Fukuoka, Japan
Yame, Fukuoka, Japan
Isahaya, Nagasaki, Japan
Hirakata, Osaka, Japan
Kanzaki Gun, Saga, Japan
Karatsu, Saga, Japan
Ogi Gun, Saga, Japan
Taito Ku, Tokyo, Japan
Yoyogi Shibuya Ku, Tokyo, Japan
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials